Swiss National Bank
ALXO icon

Swiss National Bank’s ALX Oncology ALXO Stock Holding History

Swiss National Bank’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-49,400
Closed -$298K – 2467
2024
Q2 		$298K Buy
49,400
+5,200
+12% +$63.9K ﹤0.01% 2450
2024
Q1 		$493K Buy
+44,200
New +$621K ﹤0.01% 2453
2023
Q2 		– Sell
-39,500
Closed -$179K – 2606
2023
Q1 		$179K Sell
39,500
-3,500
-8% -$26.5K ﹤0.01% 2634
2022
Q4 		$485K Hold
43,000
– – ﹤0.01% 2580
2022
Q3 		$412K Hold
43,000
– – ﹤0.01% 2621
2022
Q2 		$348K Buy
43,000
+23,800
+124% +$259K ﹤0.01% 2692
2022
Q1 		$324K Buy
19,200
+1,500
+8% +$25.6K ﹤0.01% 2655
2021
Q4 		$380K Hold
17,700
– – ﹤0.01% 2698
2021
Q3 		$1.31M Hold
17,700
– – ﹤0.01% 2305
2021
Q2 		$968K Sell
17,700
-500
-3% -$29.9K ﹤0.01% 2493
2021
Q1 		$1.34M Buy
18,200
+1,500
+9% +$118K ﹤0.01% 2226
2020
Q4 		$1.44M Buy
+16,700
New +$1M ﹤0.01% 2106

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Swiss National Bank's ALXO Position: Q3 2024 in Review

Swiss National Bank sold out of ALX Oncology (ALXO) in Q3 2024, closing a stake of 49,400 shares — an estimated $298K sold.

Swiss National Bank first reported a position in ALXO in Q4 2020 and held it in 12 quarters. The position peaked at $1.44M in Q4 2020. 92 funds tracked by Wall St. Rank hold ALXO as of Q3 2024.

  • Swiss National Bank reported no remaining ALX Oncology position as of Q3 2024 after selling out during the quarter.
  • Swiss National Bank sold 49,400 ALX Oncology shares in Q3 2024, an estimated $298K.
  • Swiss National Bank first reported a position in ALX Oncology in Q4 2020 and held it in 12 quarters.
  • Swiss National Bank's ALX Oncology position peaked at $1.44M in Q4 2020.
  • 92 funds tracked by Wall St. Rank held ALX Oncology as of Q3 2024.

Based on Swiss National Bank's 13F filing for Q3 2024, filed 7 Nov 2024.